Orthofix International NV (NASDAQ:OFIX) has been given an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.
Brokers have set a 1 year consensus price target of $50.00 for the company and are forecasting that the company will post $0.27 EPS for the current quarter, according to Zacks. Zacks has also given Orthofix International NV an industry rank of 189 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research lowered shares of Orthofix International NV from a “buy” rating to a “hold” rating in a research report on Wednesday, January 18th.
Shares of Orthofix International NV (NASDAQ:OFIX) traded up 0.85% during mid-day trading on Tuesday, hitting $38.95. 112,933 shares of the company traded hands. Orthofix International NV has a one year low of $32.51 and a one year high of $48.25. The stock has a market capitalization of $699.00 million, a price-to-earnings ratio of 234.64 and a beta of 0.36. The firm has a 50-day moving average of $37.57 and a 200-day moving average of $37.47.
Orthofix International NV (NASDAQ:OFIX) last released its quarterly earnings data on Monday, February 27th. The medical device company reported $0.42 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.05. Orthofix International NV had a net margin of 2.41% and a return on equity of 9.01%. The company earned $108.50 million during the quarter, compared to analyst estimates of $106.07 million. During the same period last year, the business earned $0.28 earnings per share. Orthofix International NV’s revenue was up 3.7% compared to the same quarter last year. On average, equities analysts predict that Orthofix International NV will post $1.52 earnings per share for the current year.
Several institutional investors have recently added to or reduced their stakes in OFIX. Aperio Group LLC raised its position in Orthofix International NV by 2.6% in the third quarter. Aperio Group LLC now owns 8,952 shares of the medical device company’s stock worth $383,000 after buying an additional 225 shares during the period. Los Angeles Capital Management & Equity Research Inc. raised its stake in shares of Orthofix International NV by 10.0% in the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 8,525 shares of the medical device company’s stock valued at $365,000 after buying an additional 775 shares during the last quarter. BlackRock Advisors LLC raised its stake in shares of Orthofix International NV by 2.8% in the third quarter. BlackRock Advisors LLC now owns 33,281 shares of the medical device company’s stock valued at $1,423,000 after buying an additional 903 shares during the last quarter. Pacad Investment Ltd. raised its stake in shares of Orthofix International NV by 150.0% in the fourth quarter. Pacad Investment Ltd. now owns 3,000 shares of the medical device company’s stock valued at $109,000 after buying an additional 1,800 shares during the last quarter. Finally, Analytic Investors LLC raised its stake in shares of Orthofix International NV by 25.9% in the third quarter. Analytic Investors LLC now owns 9,012 shares of the medical device company’s stock valued at $385,000 after buying an additional 1,856 shares during the last quarter. Institutional investors own 94.23% of the company’s stock.
About Orthofix International NV
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Orthofix International NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International NV and related companies with MarketBeat.com's FREE daily email newsletter.